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 The purpose of this study was to measure hormonal and metabolic markers in humans to 
see if simulating dehydration would emulate measures that are seen in prediabetic humans. 60 
volunteers were divided into equal categories by sex and body mass index of normal or 
overweight. Participants completed two oral glucose tolerance tests (OGTT) after being 
intravenously infused with a isotonic or hypertonic saline solution for 120 minutes in a counter 
balanced order. All trials began with a euhydrated subject with a urine specific gravity (USG) 
<1.020. Participants remained sedentary and were infused with the same amount of volume of 
solution in each trial, blood samples were taken every 30 minutes and respiratory exchange ratio 
was measured every 60 minutes. The hypertonic (HYPER) trial 120 minutes after OGTT was 
administered had significantly higher carbohydrate oxidation then that of the isotonic trial. Blood 
markers such as cortisol and aldosterone lowered significantly from baseline, but glucose was 
significantly elevated 60 and 90 minutes post infusion, reaching blood glucose levels of 
155mg/dL. Plasma osmolality rose from baseline and remained elevated throughout the duration 
of the trial. Copeptin rose significantly during the HYPER trial 30 minutes into infusion and 
remained elevated the entire length of the trial falling slightly after infusion stopped. This may 
indicate that the elevated copeptin is associated with elevated glucose levels, and carbohydrates 
as the primary fuel source
























 1  
Introduction 
 
 A report from the US Centers for Disease Control and Prevention 2014 statistics report 
claims that in the United States 29.1 million people have been diagnosed with Diabetes Mellitus 
and another 8.1 million people are currently undiagnosed with the disease. That’s almost 1 out of 
11 Americans with the disease and 1 out of 3 Americans not knowing they are prediabetic. This 
disease accounts for $254 billion dollars between direct (medical costs) and indirect costs (lost 
wages). The New England Journal of Medicine examined individuals’ fasting glucose to 
determine if those in a diabetic state (126 mg/dL) have a higher risk to develop heart disease, 
stroke, kidney failure, and premature death. The study associated diabetes with the development 
of cancers, infectious disease, intentional self-harm, and degenerative disorders, but a novel 
finding of their study was that on average 50-year old males diagnosed with diabetes died, 
approximately six years before that of their aged matched non-diabetic males.  Is it possible that 
fluid intake plays a bigger role in the development of diabetes then we think? 
 Fetissov and Thornton conducted a study with type II diabetic participants in which a low 
water intake negatively impairs glucose regulation. Fluid homeostasis and blood pressure are 
largely due to two systems, arginine vasopressin (AVP) and renin-angiotensin-aldosterone 
(RAAS). The mechanisms of AVP and RAAS play significant roles in the regulation of glucose. 
AVP has a short half-life, so its surrogate marker, copeptin is often used (Boertien, W.E., 
Riphagenm I.J., Drion, I. 2013).  Copeptin was elevated in non-diabetic and diabetic individuals 
with low water intake (Bankir L, Bardoux P, Ahloulay M 2001)(Enhorning et al. 2010)(Johnson 
EC et al. 2016). Boertein et al. also suggest that copeptin has an inverse relationship with kidney 
function. The mechanism for this is not yet known, but looking at diabetic rodent models there is 
an inverse relationship between copeptin and kidney function, it can be suggested that AVP leads 
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to hyperfiltration and then to albuminuria and glomerulosclerosis (Bankir et al 2001). Besides 
kidney function AVP plays an important role in glucose levels. As seen in Spruce et al. human 
subjects infused with AVP had an acute rise in blood glucose levels. This is most likely 
occurring at receptors V1aR and V1bR. V1aR has been connected with liver glycogenolysis and 
V1bR is associated with glucagon and insulin secretion (Keppens S, de Wulf H 1979)(Abu-
Basha EA, Yibchok-Anun S, Hsu WH. 2002). AVP can also stimulate the V1bR to release 
pituitary adrenocorticotropic hormone (ACTH) (Holmes CL, Landry DW, Granton JT 2003). An 
increase in ACTH also causes an increase in cortisol, which can lead to cortisol-mediated 
gluconeogenesis (Perraudin et al. 1993)(Rizza RA, Mandarino LJ, Gerich JE 1982). As said 
previously, the RAAS can be triggered by disturbances in body water and blood pressure 
(usually deals with a decrease in blood volume) thus causing an increase in aldosterone and renin 
(Underwood PC, Adler GK 2013). Aldosterone has been linked to insulin resistance from 
mechanisms that are involved with inhibiting effects on insulin signaling and insulin-glucose 
uptake via the glut-4 translocation in adipocytes, skeletal muscle, and vascular and smooth 
muscle cells (Luther JM, Luo P, Kreger MT et al. 2011)(Wada T et al. 2009)(Selvaraj J, Sathish 
S, Mayilvanan C, Balasubramanian K 2012). Renin also plays a role in insulin resistance due to 
the RAAS cascade it is hard to determine whether elevated renin causes a change in sensitivity or 
renin’s effects on downstream components, such as, aldosterone has a slowing effect on the 
removal of glucose from the blood (Bochud M, Nussberger J, Bovet P et al. 2006)(Wada et al. 
2009).  
 Long-term low water intake has been linked with the development of type II diabetes.  
Roussel et al. conducted a 9-year follow-up study in which water intake had an inverse 
relationship with hyperglycemia. The group observed that people who drank more than 1 L/day 
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of water had a 27% less chance of developing diabetes than people who drank less than 0.5 
L/day. When you look at dehydration and substrate utilization you will find that carbohydrates 
tend to be the primary fuel source. Hargreaves et al. conducted a study on males that exercised 
until 3% BM loss in a temperate environment (20C–22C). At 60 and 120 min of exercise a 
higher RER was measured during the fluid-restricted trial and also reported a 16% increase in 
glycogen content. Another study with similar findings is this one conducted by Gonzalez-Alonso 
et al. with seven male cyclists exercising in a hot environment (35C). They cycled until 
volitional exhaustion while developing progressive dehydration to approximately 3.9% BM loss. 
They reported increased carbohydrate oxidation, muscle glycogen use at 45% greater than the 
Euhydration trials. The aim of this study is to associate dehydration with pre-diabetic markers 
and the effects this has on metabolism and substrate utilization. I hypothesize that there will be 




Sixty total participants were needed to volunteer for this study. Males and females were divided 
into equal and separate groups. The 60 participants were divided up into two groups dependent 
upon their body mass index (BMI). This study looked at BMI’s of normal weight (18.5-25) and 
overweight individuals (27.55-35). Prior to the start of the study, the participant met with a 
research team member and filled out a health history and consent form. After consent was given, 
anthropomorphic (height, weight, waist & hip circumference and body composition via dual-
energy x-ray absorptiometry) measurements were recorded. Also, a small sample of blood was 
taken via finger stick for a glycosylated hemoglobin test (HbA1c). A value less than 6.5% was 
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needed to continue in the study, once confirmed the participant was then familiarized with a few 
perceptual scales pertaining to perception of thirst and fatigue 
Experimental Design 
To assess the effects of hydration status on glucose regulation in people, participants completed 
two identical 6 h trials. Participants were blinded to the infusion of either a isotonic saline 
solution (ISO) or hypertonic saline solution (HYPER). This allowed the subject to drink freely 
up until the start of the trial and then in the lab we kept them euhydrated with the isotonic saline 
solution, or we simulated a dehydrated state with the hypertonic saline solution. The infusion 
lasted 2 h and immediately after the infusion stops, the subject was given an oral glucose 
tolerance test (OGTT). Metabolic and endocrine markers were assessed at baseline -150 (i.e. 
immediately before) and at -120, -90, -60, -30, 0, 30, 60, 90, 120, 150, 180, 210, 240 minutes. 
Respiratory exchange ratio (RER) was assessed at baseline and every hour during the trial (-120, 








Following an approved screening procedure and participant’s consent, height and weight was 
recorded. Next, a dual x-ray absorptiometry scan (DXA; Lunar Prodigy, General Electric 
Company, Fairfield, CT, USA) was performed to assess body composition. Glycosylated 
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hemoglobin (HbA1c) was assessed via a single finger stick (Alere AfinionTM HbA1c, Waltham, 
MA, USA). The euhydrated and hypohydrated experimental visit was separated by a minimum 
of 48 hours for males. Female trials were separated by a minimum of one month and on the same 
day of their menstrual cycle. Participants are required to record a food log 24 hours prior to the 
trial, participants were instructed to choose foods high in carbohydrates. The last meal was 12 
hours before the start time of the trial. During the fast participants were instructed to drink non-
caloric beverages ad libitium. Subjects were also asked to refrain from exercise, alcohol, and 
caffeine 24 hours prior to the trial day. All of the above procedures were replicated for the 
second trial. 
Experimental Trials 
Upon arrival, a urine sample was collected for immediate  hydration status assessment via urine 
specific gravity (USG) measurement (refractometer  ATAGO, MASTER-SUR/Nα, Inc., 
Bellevue, WA) and urine osmolality by freezing point depression   (Model 3250, Advanced 
Instruments, Norwood, MA). All trials began with a euhydrated subject with a USG <1.020. 
Upon confirmation of hydration status, participants were  seated and a catheter was placed into 
an antecubital vein. Following 20 min seated rest, a 15- mL fasted blood sample was drawn, 
blood pressure, and respiratory exchange ratio (RER) were measured. The infusion was started 
and blood samples were taken, once every 30 min until the end of the 6-hour protocol. RER was 
taken once an hour (TrueOne 2400 Parvo Medics Metabolic Measurement System) where five-
minute respiratory gas measures were taken. Volume of oxygen consumed (VO2), and volume of 
carbon dioxide (VCO2) produced was used to determine the respiratory exchange ratio (Peronnet 
and Massicotte 1991) and whole body carbohydrate (CHO) and fat oxidation with the use of the 
nonprotein RER table and the following equations: CHO oxidation (g) = 4.585 (VCO2) - 3.226 
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(VO2), and fat oxidation (g) = 1.695 (VO2) - 1.701 (VCO2) (Saltin 1980; Ferrannini 1988). 
Upon completion of the trial participants were free to leave the lab, participants were given water 
and offered a meal and instructed to resume normal acts of daily living. 
Biochemical Analysis 
Blood samples were transferred into appropriate plasma or serum Vacutainer tubes immediately. 
Untreated whole blood was analyses in triplicate for hematocrit via micro-centrifugation and for 
hemoglobin via colorimetric analysis (Drabkin’s Reagent, RICCA Chemical  Laboratories, 
Arlington, TX). Vacutainer tubes were centrifuged at 1,500 g for 15 min at 4 °C. From  blood 
plasma, copeptin, aldosterone (ALDO), cortisol (CORT), were measured via enzyme-linked 
immunosorbent assay (Alpco, Salem, NH) and read on a microplate spectrophotometer 
(PowerWave HT, Biotek Winooski, VT) at 450 nm. Intra assay CVs, ALDO, and  CORT were 
6.2, 7.2, 6.5, and 5.8%, respectively. 
Statistical Analysis 
A statistical analysis was completed using the Statistical Package for the Social Sciences (SPSS, 
V22, IBM New York, NY, U.S.A.). Fasting measurements, and all measures of insulin resistance 
/ sensitivity were compared between conditions using paired- sample t-tests.  Hormone 
measurements over the course of each 4 h OGTT were compared using repeated measure 
analysis of variance. This allowed for analysis of main effects of time, condition, and the 
interaction between the two factors. When main effects were shown to be significant, individual 
time points were compared between conditions, while using a Bonferroni correction for multiple 
comparisons. Significance was established a priori at α = 0.05.   
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Results 
The subject characteristics of the 60 participants are presented in Table 1. 
 Table 1  
 Subject characteristics 






Copeptin began to rise immediately during the HYPER trials and reached approximately a five-
fold increase (20pmol/L) by the end of infusion and remained elevated throughout the remainder 
of the trial. During the ISO trial, copeptin remained at or near baseline (4pmol/L) during the 
 Female (N=30) Male (N=30) 
 Normal Obese Normal Obese 
Age (years) 41.7±9.0 41.0±7.7 35.4±6.0 37.8±7.9 
HbA1c (%) 5.4±0.3 5.1±0.2 5.1±0.2 5.3±0.3 
Height (m) 1.6±0.1 1.7±0.1 1.8±0.1 1.7±0.1 
BMI 
 
22.9±2.2 30.5±2.9 24.5±1.4 29.6±2.9 
Body Fat(%) 
 
31.5±6.1 43.3±7.3 21.4±5.8 29.7±5.4 
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entire trial (Figure 2). During the HYPER trials glucose was elevated over 126mg/dL at time 
points 60-90 min (Figure 3). Cortisol levels in both trials nearly halved from baseline measures 
(Figure 4). Aldosterone decreased in both trials from baseline measures, but after the infusion 
during the isotonic trial, measures rose slightly through the remainder of the trial (Figure 5). 
Plasma osmolality increased immediately from baseline in the HYPER trial and remained 




Figure 2. Mean Copeptin vs. Time between Hypertonic (HYPER) and Isotonic (ISO) trials. *, 
denotes differences between trials for the same time-point. †, denotes differences in comparison 
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Figure 3. Mean Glucose vs. Time between Hypertonic (HYPER) and Isotonic (ISO) trials. *, 




Figure 4. Mean Cortisol vs. Time between Hypertonic (HYPER) and Isotonic (ISO) trials. †, 
denotes differences in comparison to baseline value for the same trial. 
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Figure 5. Mean Aldosterone vs. Time between Hypertonic (HYPER) and Isotonic (ISO) trials. †, 




Figure 6. Mean Plasma Osmolality vs. Time between Hypertonic (HYPER) and Isotonic (ISO) 
trials. *, denotes differences between trials for the same time-point. †, denotes differences in 
comparison to baseline value for the same trial 
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Substrate Utilization 
The RER increased in both the HYPER and ISO trials from 60-180 minutes post infusion as a 
response to the 75g of glucose ingestion (Figure 7). Post infusion during the HYPER trial at 120 
min there was a statistically significant rise in RER (Figure 7). When RER was examined with 
Body Mass Index (BMI) the data suggests that RER is elevated post infusion 60-180 min in the 
normal BMI category and 120-180min in the obese category (Figure 8). Carbohydrate oxidation 




Figure 7. Mean RER vs. Time during Hypertonic(HYPER) and isotonic (ISO) trials. *, denotes 
differences between trials for the same time-point. ‡, denotes differences in comparison to post-





 12  
 
 
Figure 8. Mean RER vs. Time between BMI categories. ‡, denotes differences in comparison to 




Figure 9. Mean CHO vs. Time between hypertonic (HYPER) and isotonic (ISO) trials. Figure 6. 
Mean RER vs. Time between BMI categories. ‡, denotes differences in comparison to post-
infusion (0 minutes) value for the same trial. 
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Discussion 
 The purpose of this study was to measure hormonal and metabolic markers in humans to 
see if simulating dehydration would emulate measures that are seen in prediabetic humans. As 
hypothesized, after the 75g of glucose were administered, there was an elevation in carbohydrate 
metabolism in both trials. But, the hypertonic (HYPER) trial 120 minutes after OGTT was 
administered had significantly higher carbohydrate oxidation then that of the isotonic trial. Blood 
markers such as cortisol and aldosterone lowered significantly from baseline, but glucose was 
significantly elevated 60 and 90 minutes post infusion, reaching blood glucose levels of 
155mg/dL. Plasma osmolality rose from baseline and remained elevated throughout the duration 
of the trial. Increased plasma osmolality plays a significant role in stimulation AVP and 
copeptin. Copeptin rose significantly during the HYPER trial, the upward trend began 30 
minutes into infusion and remained elevated the entire length of the trial falling slightly after 
infusion stopped.  
 Fetissov and Thorton presented in their data that inadequate water consumption could 
negatively impact glucose regulation in humans with type II diabetes. This dysregulation comes 
from two systems in charge of regulation of body water and blood pressure, arginine vasopressin 
(AVP) and the renin-angiotensin-aldosterone system (RAAS). From our data we can see that the 
RAAS system, specifically the aldosterone system, was not a major factor as much as copeptin 
was since our data had approximately a 5-fold increase during the HYPER trial. Our participants 
started the trials in a euhydrated state, thus bypassing the RAAS system, which is activated 
mostly by changes in body water disturbances. When the RAAS system detects a change in body 
water or more typical; a decrease in blood volume it signals for aldosterone to up regulate as well 
as plasma renin activity. But since there was no change in blood volume or body water due to the 
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control of hydration status and infusion rates, this system did not seem to play a major role in 
glucose regulation. This is important because aldosterone has been shown to interrupt insulin 
signaling and removal of glucose from the bloodstream (Wada T, Ohshima S, Fujisawa E, Koya 
D, Tsuneki H, Sasaoka T 2009). But, in our study aldosterone decreased as infusion started, 
leaving copeptin as the main culprit for the rise in carbohydrate oxidation and glucose left in the 
plasma.  
 Other research suggests that when plasma osmolality is elevated a rise in AVP or its 
surrogate marker, copeptin can cause stimulation of V1a receptors in the liver which effects 
hepatic glycogen degradation and gluconeogenesis (Kirk CJ, Rodrigues LM, Hems DA 1979; 
Whitton PD, Rodrigues LM, Hems DA 1978). This can also be seen in a study from The 
European Journal of Clinical Nutrition where the group found an increase hepatic 
gluconeogenesis and higher plasma glucose concentrations when osmolality and AVP were 
elevated during a hyperosmolality state (Keller U, Szinnai G, Bilz S, et al. (2003). Our data 
would also suggest that increasing copeptin plays a role in an increase in plasma glucose, which 
is consistent with previous research. Our study is the first to simulate dehydration by intravenous 
infusion in humans and to measure gas exchange. During the HYPER trial while the body is in a 
simulated dehydrated state, glucose was readily available in the plasma, which could be a 
possible explanation for an increased carbohydrate oxidation from our data. Logan-Sprenger et 
al. conducted a study on female cyclists exercising in a temperate environment in a euhydrated 
and dehydrated state. The study recorded elevated carbohydrate metabolism within the 
dehydrated trials and hypothesized three possibilities for the increase in carbohydrate 
metabolism. 1) an augmented sympathoadrenal response leading to greater glycogen 
phosphorylase (PHOS) activation and flux, 2) increased allosteric activation of glycogen PHOS 
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via increased free ADP and AMP (energy status of the cell) levels, and 3) higher intramuscular 
temperature during exercise when dehydrated. Since our participants were sedentary throughout 
the entire study, possibility two and three would not be a factor. 
  In conclusion, participants began the trial in a euhydrated state; they were then infused 
with a hypertonic or isotonic saline solution for 2hrs. After the infusion stopped and OGTT was 
administered there was a spike in carbohydrate oxidation and copeptin in the blood. Even though 
participants are in a euhydrated state, the copeptin response is triggering a dehydrated response 
by reducing insulin sensitivity. This may indicate that the elevated copeptin is associated with 
elevated glucose levels, and carbohydrates as the primary fuel source. This finding is supported 
in other papers as well, specifically Roussel et al. group who conducted a community-based 
cohort in which copeptin demonstrated an increase risk diabetes by affecting insulin sensitivity. 
The study also suggested that increased water intake or vasopressin antagonist, could help 
improve metabolic status. This could be a novel finding in helping with identifying risks for the 
development of diabetes. Future studies could examine these effects in other BMI categories as 
well examining the effects of substrate utilization and metabolism with participants on controlled 
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